Contributions
Abstract: P1624
Type: LB Poster
Abstract Category: Late Breaking News
Fatigue is a frequent, disabling and difficult to treat symptom in persons with Multiple Sclerosis (pwMS) and with other stress-related conditions. Integrated Imaginative Distention (IID) is a mind-body therapy combining muscular relaxation with motor and mental imagery, feasible also in disabled subjects.
"DIMMI SI" trial (NCT02290990ClinicalTrials.gov) was planned to evaluate IID efficacy on fatigue in pwMS. Design was parallel, randomised 1:1 (intervention/waiting list), open-label. Participants were pwMS and two comparison parallel groups: persons with insomnia (pwINS) and health professionals (HP). The primary outcome was the post-intervention change of fatigue evaluated with Modified Fatigue Impact Scale (MFIS); the secondary outcomes were changes on insomnia, stress and quality of life (QoL) self-reported questionnaires. Eight IID weekly training group sessions were delivered by a skilled psychotherapist. Follow up were recorded at 2-5-8 months after IID training. Study lasted 9 months.
One hundred forty-four subjects were enrolled, 48 for each group. The mean change on total MFIS score among exposed was 7.7 [95% CI: 1.1, 14.4] (P=0.023) in pwMS; 7.1 [1.9, 12.3] (P=0.007) among pwINS, and 11.3 [4.3, 18.2] among HP (P=0.002). At the last follow up the benefit was confirmed on physical fatigue for pwMS, on cognitive fatigue for pwINS and on total scores for HP. Insomnia, stress and QoL improved on pwINS and HP but not in MS.
A clear IID impact on fatigue in pwMS was recorded, especially in physical domain and without confounder in sleep and stress-related variables, but a QoL effective improvement was not reached.
DIMMI SI is the first randomized controlled trial evaluating the efficacy of IID on fatigue. The results show that IID may be a complementary non conventional interventions advisable to reduce fatigue in pwMS.
Disclosure: A. Sgoifo: nothing to disclose
A. Bignamini: nothing to disclose
L. La Mantia: nothing to disclose
M.G. Celani: nothing to disclose
L. Nobili: nothing to disclose
P. Proserpio: nothing to disclose
MR Marazzi: nothing to disclose
V Prone: nothing to disclose
V Sangalli: nothing to disclose
MP Zagaria: nothing to disclose
A. Protti: nothing to disclose
E.C. Agostoni: nothing to disclose
Abstract: P1624
Type: LB Poster
Abstract Category: Late Breaking News
Fatigue is a frequent, disabling and difficult to treat symptom in persons with Multiple Sclerosis (pwMS) and with other stress-related conditions. Integrated Imaginative Distention (IID) is a mind-body therapy combining muscular relaxation with motor and mental imagery, feasible also in disabled subjects.
"DIMMI SI" trial (NCT02290990ClinicalTrials.gov) was planned to evaluate IID efficacy on fatigue in pwMS. Design was parallel, randomised 1:1 (intervention/waiting list), open-label. Participants were pwMS and two comparison parallel groups: persons with insomnia (pwINS) and health professionals (HP). The primary outcome was the post-intervention change of fatigue evaluated with Modified Fatigue Impact Scale (MFIS); the secondary outcomes were changes on insomnia, stress and quality of life (QoL) self-reported questionnaires. Eight IID weekly training group sessions were delivered by a skilled psychotherapist. Follow up were recorded at 2-5-8 months after IID training. Study lasted 9 months.
One hundred forty-four subjects were enrolled, 48 for each group. The mean change on total MFIS score among exposed was 7.7 [95% CI: 1.1, 14.4] (P=0.023) in pwMS; 7.1 [1.9, 12.3] (P=0.007) among pwINS, and 11.3 [4.3, 18.2] among HP (P=0.002). At the last follow up the benefit was confirmed on physical fatigue for pwMS, on cognitive fatigue for pwINS and on total scores for HP. Insomnia, stress and QoL improved on pwINS and HP but not in MS.
A clear IID impact on fatigue in pwMS was recorded, especially in physical domain and without confounder in sleep and stress-related variables, but a QoL effective improvement was not reached.
DIMMI SI is the first randomized controlled trial evaluating the efficacy of IID on fatigue. The results show that IID may be a complementary non conventional interventions advisable to reduce fatigue in pwMS.
Disclosure: A. Sgoifo: nothing to disclose
A. Bignamini: nothing to disclose
L. La Mantia: nothing to disclose
M.G. Celani: nothing to disclose
L. Nobili: nothing to disclose
P. Proserpio: nothing to disclose
MR Marazzi: nothing to disclose
V Prone: nothing to disclose
V Sangalli: nothing to disclose
MP Zagaria: nothing to disclose
A. Protti: nothing to disclose
E.C. Agostoni: nothing to disclose